Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck’s Hyzaar Approved For Stroke Prevention

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA approval is based on results of the LIFE outcomes study; Cozaar was approved for same indication in March 2003. Like Cozaar, the benefit of Hyzaar in stroke prevention does not appear to be applicable to black patients, labeling says.

You may also be interested in...



Merck Adds New Titration Dose For Hyzaar Antihypertensive

New 100-12.5 mg dose could be the starting point for patients whose hypertension is not controlled by Cozaar alone.

Merck Adds New Titration Dose For Hyzaar Antihypertensive

New 100-12.5 mg dose could be the starting point for patients whose hypertension is not controlled by Cozaar alone.

Merck's Hyzaar Adds Front-Line Severe Hypertension Indication

The antihypertensive was previously indicated for initial use only when hypertension was severe enough that the value of promptly controlling blood pressure exceeded the risk of therapy with the losartan/hydrochlorothiazide combination.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS061993

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel